Cheng Chi Wang
Chief Tech/Sci/R&D Officer at LIN BIOSCIENCE, INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Yue Hsin Lin | M | 46 |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | 8 years |
Hao Yuan Chuang | M | 40 | 7 years | |
Hung Wei Chen | F | 43 | 8 years | |
San Chien Tu | M | - | 6 years | |
Hui Chun Wang | M | 78 | 6 years | |
Wei Jen Liang | M | - | 6 years | |
Wan Shan Chen | F | 38 | 8 years | |
Hsien Hua Huang | M | - | 6 years | |
Nathan L. Mata | M | 58 |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The private company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | 3 years |
Chan Yue Li | M | 52 | 8 years | |
Cheng Wei Chu | M | - | 6 years | |
Fang Ming Hsu | M | - | 8 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ming Chiu Wu | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
Taiwan | 12 | 92.31% |
United States | 2 | 15.38% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Cheng Chi Wang
- Personal Network